ArticleEuropean heart journal2021
C-reactive protein and clinical outcomes in patients with COVID-19.
Article in European heart journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04898062 (Randomized, Controlled, Proof-Of-Concept Trial of CRP-Apheresis for Attenuation of Pulmonary MYocardial and/or Kidney Injury in COvid-19), which is not on this map. Cited by 232 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Controlled, Proof-Of-Concept Trial of CRP-Apheresis for Attenuation of Pulmonary MYocardial and/or Kidney Injury in COvid-19
Who cites it
232 citing papers in PubMed, 2 syntheses or guidelines pooled it, 449 citations in OpenAlex.
- Accuracy of routine laboratory tests to predict mortality and deterioration to severe or critical COVID-19 in people with SARS-CoV-2.The Cochrane database of systematic reviews · 2024Pooled it
- Updated Living Systematic Review and Meta-analysis of Controlled Trials of Mesenchymal Stromal Cells to Treat COVID-19: A Framework for Accelerated Synthesis of Trial Evidence for Rapid Approval-FASTER Approval.Stem cells translational medicine · 2022Pooled it
- Analysis of Virologic and Clinical Predictors for Hospitalization, Supported by Machine Learning, in a Phase 3 Molnupiravir COVID-19 Treatment Trial.Clinical and translational science · 2026Trial
- Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant.Pathogens (Basel, Switzerland) · 2025Trial
- Trial
- RIC in COVID-19-a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19.Cardiovascular drugs and therapy · 2022Trial
- Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial.Annals of internal medicine · 2022Trial
- Prognostic Value of the Lactate-to-Albumin and C-Reactive Protein-to-Albumin Ratios in COVID-19-Associated ARDS.Journal of clinical medicine · 2026Article
- Development and External Validation of a Postoperative Risk Score for Venous Thromboembolism in Epithelial Ovarian Cancer.The Kaohsiung journal of medical sciences · 2026Article
- ICU Admission and Post-Discharge Mortality in COVID-19: Different Risk Factors Across Clinical Phases.Medical sciences (Basel, Switzerland) · 2026Observational
- C-Reactive Protein Trajectories by Summary Metric Across the Coronavirus-2019 Period: A 16-Year Interrupted Time-Series Analysis (2008-2023).Diagnostics (Basel, Switzerland) · 2026Article
- New Simplified White Blood Cells Score Improves Mortality Prediction in Severe COVID-19 Patients.Journal of clinical medicine · 2026Article
- Post-COVID-19 Outcomes of Patients with Autosomal Dominant Polycystic Kidney Disease: A Multicenter Controlled Study.Journal of clinical medicine · 2026Article
- Plasma Ceramides Levels in Severe COVID-19 Disease: Correlations with Survival.Open forum infectious diseases · 2026Article
- Exploring blood transcriptional signatures for thrombosis diagnosis in critically ill patients with COVID-19.Blood vessels, thrombosis & hemostasis · 2026Article
- Hospitalization outcomes and laboratory correlations in pediatric MIS-C patients: a retrospective cross-sectional study in Tehran, Iran.BMC pediatrics · 2026Article
- Venous thromboembolism in hospitalized patients with COVID-19: clinical and laboratory characteristics at three tertiary care centers in a state capital in the Eastern Amazon.Jornal vascular brasileiro · 2026Article
- Validation of CURB-65, CRB-65, NEWS2, qSOFA, and 4C scores for predicting mortality in COVID-19 patients across seven emergency Departments in Colombia.Frontiers in medicine · 2026Article
- A novel diagnostic model for brucellosis spondylitis using serum PINP and inflammatory factors: a dual-cohort study from Northwest China.BMC infectious diseases · 2025Article
- Determination and comparison of serum C-reactive protein levels in patients with Omicron and Delta strains of COVID-19 hospitalized in Imam Khomeini Hospital, Urmia, 2021.BMC infectious diseases · 2025Article
172 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundA systemic inflammatory response is observed in coronavirus disease 2019 (COVID-19). Elevated serum levels of C-reactive protein (CRP), a marker of systemic inflammation, are associated with severe disease in bacterial or viral infections. We aimed to explore associations between CRP concentration at initial hospital presentation and clinical outcomes in patients with COVID-19. METHODS AND
resultsConsecutive adults aged ≥18 years with COVID-19 admitted to a large New York healthcare system between 1 March and 8 April 2020 were identified. Patients with measurement of CRP were included. Venous thrombo-embolism (VTE), acute kidney injury (AKI), critical illness, and in-hospital mortality were determined for all patients. Among 2782 patients hospitalized with COVID-19, 2601 (93.5%) had a CRP measurement [median 108 mg/L, interquartile range (IQR) 53-169]. CRP concentrations above the median value were associated with VTE [8.3% vs. 3.4%; adjusted odds ratio (aOR) 2.33, 95% confidence interval (CI) 1.61-3.36], AKI (43.0% vs. 28.4%; aOR 2.11, 95% CI 1.76-2.52), critical illness (47.6% vs. 25.9%; aOR 2.83, 95% CI 2.37-3.37), and mortality (32.2% vs. 17.8%; aOR 2.59, 95% CI 2.11-3.18), compared with CRP below the median. A dose response was observed between CRP concentration and adverse outcomes. While the associations between CRP and adverse outcomes were consistent among patients with low and high D-dimer levels, patients with high D-dimer and high CRP have the greatest risk of adverse outcomes.
conclusionsSystemic inflammation, as measured by CRP, is strongly associated with VTE, AKI, critical illness, and mortality in COVID-19. CRP-based approaches to risk stratification and treatment should be tested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.